[Skip to Content]
[Skip to Content Landing]
Views 177
Correction
July 19, 2019

Error in Payments From Some Pharmaceutical Companies

JAMA Netw Open. 2019;2(7):e198619. doi:10.1001/jamanetworkopen.2019.8619

In the Original Investigation titled “Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan,”1 published May 17, 2019, payments from some pharmaceutical companies were double-counted. A complete itemization of corrections is as follows: (1) the number of authors who received payments and the percentage of payments accounted for by corresponding authors in the Key Points; (2) the number of authors who received payments, the percentage of payments accounted for by corresponding authors, and the payment value in the abstract; (3) the number of authors who received payments, the percentage of payments accounted for by corresponding authors, and the payment value in the Results section; (4) the percentage of authors who received payments, the percentage of payments accounted for by corresponding authors, and the payment value in the Discussion section; (5) the number of authors who received payments in the Conclusions section; (6) the payment value and the number of authors who received payments in Table 2; and (7) the payment value and the number of authors who received payments in Table 3. This article has been corrected.1

References
1.
Sawano  T, Ozaki  A, Saito  H, Shimada  Y, Tanimoto  T.  Payments from pharmaceutical companies to authors involved in the valsartan scandal in Japan.  JAMA Netw Open. 2019;2(5):e193817. doi:10.1001/jamanetworkopen.2019.3817PubMedGoogle ScholarCrossref
×